Still, he said, there is likely not enough of a benefit from the
BID schedule to sway patients who have already deferred treatment. While
BID is better than TID, it is still a complicated regimen, he noted.
Dr Don Jensen, professor of medicine, director, Center for Liver Diseases, University of Chicago, agreed some physicians are likely already using the BID schedule. The BID regimen does make it easier for some patients to manage their therapy, as ribavirin is also dosed BID.